Literature DB >> 17535338

Caring for patients with allergic rhinitis.

Mary Lou Hayden1, Catherine R Womack.   

Abstract

PURPOSE: Allergic rhinitis (AR) affects up to 40 million Americans, with an estimated cost of $2.7 billion per annum. This review discusses several therapeutic options that reduce the symptoms of AR, including allergen avoidance, antihistamines, intranasal corticosteroids (INS), leukotriene receptor antagonists, and immunotherapy. DATA SOURCES: The articles included in this review were retrieved by a search of Medline literature on the subjects of AR, antihistamines, INS, leukotriene antagonists, and immunotherapy, as well as current published guidelines for the treatment of AR.
CONCLUSIONS: Allergen avoidance is recommended for all patients prior to pharmacologic therapy. Oral and nasal H(1)-antihistamines are recommended to alleviate the mild and intermittent symptoms of AR, and INS are recommended as the first-line treatment choice for mild persistent and more moderate-to-severe persistent AR. IMPLICATIONS FOR PRACTICE: There are a number of different types of therapy for the management of AR; with so many options available, successful tailoring of treatment to suit individual requirements is realistically achievable.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17535338     DOI: 10.1111/j.1745-7599.2007.00228.x

Source DB:  PubMed          Journal:  J Am Acad Nurse Pract        ISSN: 1041-2972


  1 in total

1.  Strategies for the management of intermittent allergic rhinitis: an Australian study.

Authors:  Lorraine Smith; Lin Brown; Bandana Saini; Celina Seeto
Journal:  Health Expect       Date:  2012-02-01       Impact factor: 3.377

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.